Xylem Inc. · XYL · FY2024 Q2 · Calendar Q3 2024

Xylem’s Q2 growth and raised outlook underscore execution focus

The call presented a strong quarter, raised full-year outlook, and ongoing integration and simplification work as supports for Xylem’s growth narrative. The durability of that picture depends on execution amid project timing, macroeconomic, and regulatory uncertainties.

Why did XYL fall 5.7% after beating EPS estimates in FY2024 Q2?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEIndustrials $21.60B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.09 Consensus $1.05
EPS surprise +3.8% Reported versus consensus
Reported revenue $2.17B Consensus $2.14B
Revenue surprise +1.1% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move -5.7% Event window
SPY move -0.5% Same window
Abnormal move -5.2% Stock minus SPY
Volume 2.7× Versus trailing sessions
Subsequent drift +1.5% Up to 20 sessions
XYLSPY benchmark

Ask FN2 about XYL FY2024 Q2

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Management said Q2 performance exceeded guidance, with revenue up 26% and adjusted EBITDA margin expanding 170 basis points. It raised full-year revenue guidance by $50 million and the EPS midpoint by $0.06, while describing Evoqua integration and the 80/20 simplification program as ongoing priorities.

Guidance delta

Raised full-year revenue guidance by $50 million and the EPS midpoint by $0.06, according to the call analysis; the supplied facts do not state the revised absolute guidance ranges.

Key takeaways

  • Q2 revenue grew 26%, with 9% organic growth, and adjusted EBITDA margin expanded 170 basis points.
  • Measurement & Control Solutions revenue grew 26% and its margin improved 700 basis points.
  • Management raised full-year revenue guidance by $50 million and the EPS midpoint by $0.06.
  • The call described Evoqua integration as progressing and the 80/20 simplification effort as an ongoing initiative.

Management priorities

  • Continue implementing the 80/20 simplification program across segments.
  • Pursue $100 million in run-rate cost synergies from the Evoqua integration.
  • Seek opportunities in data centers, green hydrogen, pharma, and microelectronics.

Follow XYL with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
XYL EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $0.96 Q4 '23 actual $0.99, beat Q1 '24 estimate $0.84 Q1 '24 actual $0.90, beat Q2 '24 estimate $1.05 Q2 '24 actual $1.09, beat Q3 '24 estimate $1.11 Q3 '24 actual $1.11, match Q2 '25 estimate $1.15 Q2 '25 actual $1.26, beat Q3 '25 estimate $1.23 Q3 '25 actual $1.37, beat Q4 '25 estimate $1.41 Q4 '25 actual $1.42, match Q1 '26 estimate $1.08 Q1 '26 actual $1.12, beat Q2 '26 estimate $1.35 Q2 '26 actual $1.46, beat Q3 '26 estimate $1.45 Q3 '26 actual $1.44, match Q4 '26 estimate $1.63 Q1 '27 estimate $1.17
Show less

Analyst Consensus ?

ConsensusHold40 ratings
Bullish1845.0%
Neutral2050.0%
Bearish25.0%

Analyst 52W Price Targets

$94.66Current
$90Low
$137.93Average
$170High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Argus Research Hold BuyDowngradeNov 4, 2026
UBS Neutral NeutralMaintainOct 29, 2026
Barclays Equal Weight OverweightDowngradeOct 29, 2026
Stifel Buy BuyMaintainOct 28, 2026
RBC Capital Outperform OutperformMaintainOct 28, 2026
Show 35 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $94.66. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BarclaysWilliam Grippin$104$88.23 +9.9%Oct 28, 2026
Mizuho SecuritiesBrett Linzey$99$92.86 +4.6%Oct 28, 2026
Robert W. BairdMichael Halloran$123$92.86 +29.9%Oct 28, 2026
Goldman SachsBrian Lee$138$92.86 +45.8%Oct 28, 2026
RBC CapitalJeffrey Reive$125$92.86 +32.1%Oct 28, 2026
See 55 more

Track every rating change on XYL the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Xylem Inc., together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for utility, industrial, and residential and commercial building services settings worldwide. It operates through Water Infrastructure; Applied Water; Measurement and Control Solutions; and Water Solutions and Services segments. The company offers water, wastewater, and storm water pumps and controls and systems; filtration, disinfection, and biological treatment equipment under the Flygt, Ionpure, Leopold, Neptune Benson, Sanitare, Wallace & Tiernan, and Wedeco brands; and pumps, valves, heat exchangers, controls, and dispensing equipment used for water and focuses on the residential, commercial and industrial markets under the Rule, Bell & Gossett, Flojet, Goulds Water Technology, Jabsco, and Lowara brands.…

Historical context

All XYL earnings

Industrials peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the XYL recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
  3. Polygon adjusted daily market bars · 2026-11-16T11:00:46.772418+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-16T11:00:46.769595+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-16. For educational purposes only; not investment advice.